# Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients

> **NCT04483284** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 28 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** TACE combined with Camrelizumab
- **PROCEDURE:** TACE plus Camrelizumab

## Key facts

- **NCT ID:** NCT04483284
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-24
- **Primary completion:** 2024-12
- **Final completion:** 2025-05
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04483284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04483284, "Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04483284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*